



<https://doi.org/10.34883/PI.2024.13.1.020>



Al-Amiri R.M.¹✉, Kadhum H.S.², Ali F.M.³

¹ College of Dentistry, Basrah, Iraq

² College of Science, Basrah, Iraq

³ College of Medicine, Basrah, Iraq

Estimate the Effect of Age Pre and Post Sleeve Gastrectomy on Liver Functions

Conflict of interest: nothing to declare.

Authors' contribution: Al-Amiri R.M. – conceptualization, methodology, investigation, resources, data curation, writing – original draft; Kadhum H.S. – supervision, conceptualization, methodology, data curation, writing – original draft; Ali F.M. – supervision, conceptualization, methodology, writing – original draft.

Informed consent: informed consent was obtained from all patients, and their identities remained anonymous during the entire study process.

The article is published in the author's edition.

Submitted: 14.09.2023

Accepted: 11.03.2024

Contacts: rawaqjasim@gmail.com

Abstract

Introduction. The obesity is markedly increasing in low-income and middle-income countries. Bariatric surgery has proven to be effective in treating obesity and its related diseases. The liver is the largest intracorporeal organ in the human body and plays a predominant role in several pivotal functions to maintain normal physiological activities.

Purpose. To demonstrate the effect of age on patients pre and post sleeve gastrectomy on liver functions.

Materials and methods. This study was conducted at Al-Basrah metabolic and Bariatric Surgery Centre, Iraq, from December 2021 to March 2022, on 52 patients with morbid obesity treated by sleeve gastrectomy. Patients were divided into three age categories and two groups according to the periods of their operation. The first group was collected before the operation, the second group was collected after six months of the operation.

Results. There is a significant reduction in BMI after 6 months in first and second categories of age, there was significant lower in ALT and ALP after 6 months in first and second categories of age. Regarding AST there is only significant reduction in the second category and there is a significant increase in INR in the first category.

Conclusion. The excess weight loss tended to increase with decreasing age, AST, ALT, ALP this enzyme levels before and after the surgery can provide insights into liver function and potential liver-related effects of the procedure and age have effect on INR level.

Keyword: sleeve gastrectomy, liver functions, bariatric surgery, middle-income countries, obesity, AST, ALT, INR

Аль-Амири Р.М.¹✉, Кадхум Х.С.², Али Ф.М.³

¹ Стоматологический колледж, Басра, Ирак

² Колледж естественных наук, Басра, Ирак

³ Медицинский колледж, Басра, Ирак

Оценка влияния возраста пациентов на показатели функции печени до и после рукавной гастрэктомии

Конфликт интересов: не заявлен.

Вклад авторов: Аль-Амири Р.М. – концепция исследования, методология, проведение исследований, привлечение ресурсов, обработка данных, написание исходного текста статьи; Кадхум Х.С. – научное руководство, концепция исследования, методология, обработка данных, написание исходного текста статьи; Али Ф.М. – научное руководство, концепция исследования, методология, написание исходного текста статьи.

Информированное согласие: от всех пациентов были получены информированные согласия, анонимность сохранялась в течение всего исследования.

Статья опубликована в авторской редакции.

Подана: 14.09.2023

Принята: 11.03.2024

Контакты: rawaqjasim@gmail.com

Резюме

Введение. В странах с низким и средним уровнем дохода наблюдается заметный рост числа людей с ожирением. Бариатрическая хирургия доказала свою эффективность в лечении ожирения и связанных с ним заболеваний. Печень является крупнейшим внутриполостным органом человеческого тела и играет первостепенную роль в выполнении ряда важнейших функций по поддержанию нормальной жизнедеятельности организма.

Цель. Изучение влияния возраста пациентов на функции печени до и после рукавной гастрэктомии.

Материалы и методы. Данное исследование проводилось в Центре метаболической и бариатрической хирургии Аль-Басра, Ирак, с декабря 2021 г. по март 2022 г. В исследовании участвовали 52 пациента с патологическим ожирением, которые подверглись рукавной гастрэктомии. Пациенты были разделены на три возрастные категории и две группы согласно срокам проведения операции. Первая группа была сформирована до операции, вторая – через 6 месяцев после операции.

Результаты. Отмечено достоверное снижение ИМТ через 6 месяцев в первой и второй возрастных категориях, достоверное снижение уровней АЛТ и АЛП через 6 месяцев в первой и второй возрастных категориях. Что касается АСТ, то достоверное снижение отмечено только у пациентов второй категории, а достоверное повышение МНО – у пациентов первой категории.

Заключение. Выявлена следующая закономерность: потеря избыточного веса была выше у лиц более молодого возраста. Уровни АСТ, АЛТ, АЛП до и после операции позволяют оценить функцию печени и потенциальные последствия оперативного вмешательства для ее функционирования; возраст пациента влияет на показатели МНО.

Ключевые слова: рукавная гастрэктомия, функциональные показатели печени, бариатрическая хирургия, страны со средним уровнем дохода, ожирение, АСТ, АЛТ, МНО



■ INTRODUCTION

Obesity is a condition characterized by an excessive accumulation of fat in the body [1], to the extent that it may impact one's health [2]. Obesity is a major public health issue all around the world [3]. The prevalence of obesity is also markedly increasing in low-income and middle-income countries [4]. Therefore, if these trends continue, by 2025, the global prevalence of obesity will reach 18% in men and >21% in women, with severe obesity surpassing 6% and 9%, respectively [5]. Therefore, Bariatric surgery has proven to be effective in treating obesity and its related diseases [6]. Sleeve gastrectomy, is a surgical weight-loss procedure in which the stomach is reduced to about 15% of its original size, by the surgical removal of a large portion of the stomach, following the major curve. The open edges are then attached together to leave the stomach shaped more like a tube, or a sleeve, with a banana shape [7].

The liver is the largest intracorporeal organ in the human body and plays a predominant role in several pivotal functions to maintain normal physiological activities [8]. An organ as complex as the liver can experience a range of problems including fatty liver disease, hepatitis, cirrhosis, hepatocellular carcinoma and cholangiocarcinoma [9]. It is an organ considered as the most significant organ for detoxification and protein synthesis, both of which are facilitated by a number of enzymes. Therefore, analyse liver health is represented by estimating the enzymes that released from liver cells and proteins that created by the liver and released into the blood stream [10]. The most common tests of liver function include total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) [11]. Whereas, bilirubin is the break down product of haemoglobin produced within the reticuloendothelial system, emitted in unconjugated (indirect bilirubin) (BiliND) form which enters into the liver, converted to conjugated (direct bilirubin) (Bili D) forms bilirubin mono and diglucuronides by the enzyme UDP-glucuronyl transferase [12].

As AST can be rise in diseases affecting other organs, involve acute haemolytic anaemia, pancreatitis, myocardial infarction, burns, muscular skeletal diseases and acute kidney injury. Thus, ALT is more specific for liver inflammation and disease than AST. In addition to that, clearance of serum aminotransferases involves catabolism by the reticuloendothelial system, and in that assessment, is comparable to the clearance of other serum proteins. AST is consumption more rapidly than ALT, and the major site of clearance is the hepatic sinusoidal cell [13]. At the same time, alkaline phosphatase is important enzyme in the subject, which represents a group of isoenzymes created by liver, kidneys, bones, placenta and small intestine [14]. The serum Alkaline phosphatase (ALP) level signifies the total quantities of isoenzymes that are released from the specialized tissues into the blood stream and its major function is thought facilitate transport across cell membranes and assistance in metabolism [15]. Prothrombin time (PT/INR) whereas the PT is a measure of the integrity of the extrinsic and final common pathways of the procoagulant cascade. The PT represents the time, in seconds, for patient plasma to clot after the addition of calcium and an activator of the extrinsic pathway (thromboplastin). Thus, deficiencies or inhibitors of clotting factors within the extrinsic and final common pathways result in prolongation of the PT and the INR is a mathematical conversion of a patient's PT that accounts for the sensitivity of the thromboplastin used in a given laboratory by factoring in the international sensitivity index (ISI) value supplied by its manufacturer [16].

The two laboratory tests are used to evaluate coagulation disorders where the PT test measures the time it takes for blood to clot in response to prothrombin, a clotting factor, activation, and the PTT test measures the time it takes for blood to clot in response to clotting factor activation [17].

The International Normalised Ratio (INR) is calculated as follows: $INR = \frac{\text{patient PT}}{MNPT}^{ISI}$, in which MNPT is the geometric mean of the PT of at least 20 healthy subjects of both sexes tested at the performing laboratory. Since its introduction, INR has reduced the interlaboratory variations in PT results [18]. A number of researchers including Meyer et al., and Donaldson et al. they suggested that liver enzymes abnormalities have relationship with obesity, hormone therapy or autoimmunity [19, 20].

Some studies show that bariatric surgery causes the changes in intestinal anatomy and metabolism may precipitate severe hepatic complications under certain circumstances [21].

Liver-related complications or adverse outcomes following BS suggest that we should pay attention to the evaluation of liver status after surgery [22, 23]. Bariatric surgery (BS) can improve the adverse metabolic status and hepatocellular pathological status of nonalcoholic fatty liver disease (NAFLD) [24, 25]. Several clinical studies have shown that bariatric surgery has an important positive impact on the liver, with improvements of liver enzymes and liver histology [26, 27].

Patient's age is a crucial determinant for many medical interventions, including the results of Bariatric surgery. Differences in energy requirements, psychological condition as well as physiopathological and behavioral hypothesis may explain the association between age and weight loss after bariatric treatment. No upper age limit for bariatric surgery was recommended by the consensus panel. At the time of publication, it was felt that insufficient data was available to make a recommendation for or against surgery in the adolescent population. However, multiple studies have now shown bariatric surgery to be safe in both extremes of age [28]. The results of sleeve gastrectomy may differ depending on patient's age, a few reported studies suggest that younger patients may achieve more satisfactory weight loss results. However, these studies were carried out for a shorter followup, and as it is known, long-term observation is crucial to analyse the effects of BS [29].

■ PURPOSE OF THE STUDY

To demonstrate the effect of age on patients pre and post sleeve gastrectomy on liver functions.

■ MATERIALS AND METHODS

Study Population

This is a prospective study will be carried out on 52 patients with morbid obesity by sleeve gastrectomy, with age about 18–59 years for about 10-months duration at Al-Basra metabolic and Bariatric Surgery Center Iraq, the southern part of Iraq. All patient will be subjected to questioner including: age, sex, marital state BMI, chronic disease, drugs history. Blood sample will be drawn at preoperative time, and sex months after surgery, for LFT, PT, PTT, INR.

Required data that were collected by the researcher depend on a direct interview with patients before the operation and being admitted to the study, using the questionnaire, which includes data on items such as age, sex, height, weight and geographical area.

Exclusion criteria are diabetes, cardiomyopathy, chronic liver disease, liver cirrhosis and chronic hepatitis (hepatitis B and hepatitis C), also drugs that cause abnormal liver enzymes or prolong PT and INR like statin or warfarin and alcoholic drinker.

Patient's weight was measured while they were standing without shoes using the same scale for all patients (Detecto, model 339, physician scale with height rod eye level, max. 180 kg ± 0.1 kg, Philippine).

Study Design

Patients were divided into three age groups and two groups according to the periods of their operation. The first group was collected before the operation, the second group was collected after six months of the operation. BMI was calculated as Body Mass Index = Weight (kg) / height (m2).

Blood samples

A total (3.5 ml) of blood will draw from the patient preoperational and post operation and subdivided to (2 ml) of whole blood for PT (prothrombin time) and INR (international normalized ratio), and (1.5 ml) serum for liver function teste (LFT) include:

- a. Total serum bilirubin both direct and indirect.
- b. Liver enzymes (ALT alanine transaminase and AST aspartate aminotransferase).
- c. Alkaline phosphatase.

■ **RESULTS**

As shown in table (1) there is significant reduction in BMI after 6 months in first and second categories of age, although there is reduction in BMI in the third category but it is statistically not significant.

Table 2 shown no significant in bilirubin after six months in all categories of age.

In Table (3) we found that there was significant reduction in ALT and ALP after 6 months in first and second categories of age, although there is reduction in ALT and ALP in the third category but it is statistically not significant. Regarding AST there is only significant reduction in the second category.

Table (4) shown only significant increase in INR in the first category, while not significantly increase in the second and third categories and there are no significant changes in the other parameters.

Table 1
Comparison between (G1) and (G3) according to the Age, regarding the BMI

Variables	Age Groups					
	15–30 years		31–45 years		46–60 years	
	Mean±SD	Median (Min.–Max.)	Mean±SD	Median (Min.–Max.)	Mean±SD	Median (Min.–Max.)
BMI before	44.5411±5.94901	44.0800 (35.43–55.16)	46.9378±11.15499	43.2500 (37.66–79.04)	44.4444±8.54185	44.0600 (31.48–58.94)
BMI after six months	32.2711±6.21078	31.1400 (22.53–45.17)	33.5360±5.56526	33.2600 (24.49–42.15)	31.5600±3.74276	33.0300 (26.57–35.94)
P-value	0.001		0.0001		0.08	

Table 2
Comparison between (G1) and (G3) according to the Age, regarding the TSB, Bili D, and Bili IND

Variables	Age Groups					
	15–30 years		31–45 years		46–60 years	
	Mean±SD	Median (Min.–Max.)	Mean±SD	Median (Min.–Max.)	Mean±SD	Median (Min.–Max.)
TSB before	0.8326±0.35258	0.7200 (0.50–2.10)	0.8343±0.41630	0.7000 (0.28–22.2)	0.7456±0.24419	0.7200 (0.45–1.28)
TSB after six months	0.7239±0.37234	0.6400 (0.35–1.81)	0.7515±0.31035	0.6600 (0.38–1.67)	0.7080±0.302	0.6500 (0.36–1.20)
P-value	0.327		0.455		0.893	
Bili D before	0.2826±0.16776	0.2400 (0.10–0.60)	0.2913±0.16821	0.2700 (0.10–0.68)	0.2256±0.18467	0.1700 (0.05–0.65)
Bili D after six months	0.2839±0.20371	0.1800 (0.11–0.90)	0.2525±0.12443	0.2250 (0.11–0.62)	0.3200±0.23622	0.2000 (0.14–0.70)
P-value	0.925		0.349		0.715	
Bili IND before	0.5495±0.37064	0.5200 (0.17–0.199)	0.5430±0.37986	0.4800 (0.12–1.94)	0.5167±0.08078	0.5400 (0.40–0.64)
Bili IND after six months	0.4389±0.27101	0.4000 (0.18–1.31)	2.2820±7.93970	0.5050 (0.18–36.00)	0.3880±0.16634	0.5000 (0.16–0.51)
P-value	0.240		0.970		0.138	

Table 3
Comparison between (G1) and (G3) according to the Age, regarding the AST, ALT, and ALP

Variables	Age Groups					
	15–30 years		31–45 years		46–60 years	
	Mean±SD	Median (Min.–Max.)	Mean±SD	Median (Min.–Max.)	Mean±SD	Median (Min.–Max.)
AST before	29.00±8.869	28.00 (17–51)	38.43±42.442	31.00 (15–229)	26.67±8.031	28.00 (14–37)
AST after six months	23.72±9.815	22.00 (14–42)	22.90±7.181	21.50 (11–38)	28.20±7.225	30.00 (18–36)
P-value	0.150		0.012		0.343	
ALT before	35.00±16.826	28.00 (16–85)	41.13±43.686	36.00 (12–236)	28.44±10.442	30.00 (13–39)
ALT after six months	19.50±8.920	18.00 (11–44)	18.55±4.419	18.50 (10–29)	22.40±9.370	19.00 (12–35)
P-value	0.002		0.000		0.416	
ALP before	200.74±48.415	202.00 (109–301)	198.43±58.920	194.00 (100–337)	211.22±37.745	229.00 (146–262)
ALP after six months	114.61±64.392	79.00 (60–240)	130.75±57.117	115.50 (63–250)	160.80±58.410	194.00 (68–205)
P-value	0.003		0.0001		0.500	

Table 4
Comparison between (G1) and (G3) according to the Age, regarding the PT, PTT, and INR

Variables	Age Groups					
	15–30 years		31–45 years		46–60 years	
	Mean±SD	Median (Min.–Max.)	Mean±SD	Median (Min.–Max.)	Mean±SD	Median (Min.–Max.)
PT before	14.1474±3.81858	13.4000 (11.70–29.30)	14.5352±4.84620	13.4000 (8.11–29.70)	13.6333±1.02225	13.7000 (12.00–15.20)
PT after six months	14.9856±5.80677	14.3500 (2.14–34.70)	15.4900±4.18480	14.6500 (12.10–32.10)	14.5800±2.59557	14.1000 (12.30–18.80)
P-value	0.113		0.079		0.686	
PTT before	32.5842±7.11144	31.4000 (24.90–58.00)	33.6130±9.18563	33.6130 (23.20–68.80)	33.8478±4.54833	32.7000 (28.00–41.10)
PTT after six months	32.7278±5.77365	31.8500 (26.30–52.40)	32.8600±5.10649	30.6000 (26.90–48.60)	30.4000±2.73313	31.3000 (25.60–32.10)
P-value	0.777		0.881		0.225	
INR before	1.2226±0.34297	1.1600 (0.90–2.55)	1.2822±0.43453	1.1500 (0.96–2.68)	1.1844±0.08777	1.1900 (1.04–1.33)
INR after six months	1.3944±0.45358	1.2650 (1.15–3.16)	1.3765±.38617	1.2800 (1.08–2.91)	1.2700±.35010	1.2300 (0.36–1.20)
P-value	0.006		0.073		0.686	

■ DISCUSSION

In this study when compare between the level BMI according to the age, the present study found that there is significant difference ($P=0.001$, $P=0.001$) between patients before and after 6 months of surgery through the first and second age categories and that is in agreement with [30] who said that younger age is associated with better weight loss. In our study there is reduction in the body weight in third category but not statistically significant. It may be due to the fact that elderly patients exercised less and had more comorbidities. The excess weight loss tended to increase with decreasing age, probably resulting from stricter adherence of younger patients to exercise programs and diet changes advised by dietitians. Other reasons that older patients with higher BMI are unable to get as close to a BMI 24.9 could include excess this agreement with [31, 32].

So, when compare the level of AST according to the age, we found that there is a statistically significant lower in patients second category of age ($P=0.012$) and not statistically significant lower in patients first and third categories of age between patients before and after 6 months of surgery.

This disagreement with [33]. Changes in this enzyme levels before and after the surgery can provide insights into liver function and potential liver-related effects of the procedure.

AST is a liver enzyme that plays a vital role in various metabolic processes, including protein metabolism. SG which involves the removal of a significant portion of the stomach, leading to changes in gastrointestinal anatomy and metabolic processes, therefore comparing AST values between different age groups before and after sleeve gastrectomy can help researchers and healthcare professionals understand how age influences liver function and the impact of the surgery on different age categories. This needs further studies and research.

Moreover, the current study showed that there is a significant reduction in first and second age categories in ALT level ($P=0.002$, 0.000) respectively. Similar results were

reported previous study Venâncio F.A. et al. whose said that serum liver enzymes such as AST and ALT are biomarkers of liver function and injury. An increase in the serum levels of these enzymes is associated with hepatocyte injury and inflammation [34]. The increase of serum liver transaminases observed in RYGB operation, suggests worsening of hepatic function in these patients. Although most studies have reported beneficial effects of BS on liver function, including a reversal of pathological liver changes [35] some studies found an increased risk of progressive liver dysfunction and worsening of inflammation and fibrosis following RYGB [35, 36]. This fact might be partially attributed to the malabsorption that occurs after RYGB [37], and in SG there is no malabsorption. On the other hand, the significant decrease of serum liver transaminases observed in the SG group is consistent with previous reports [38].

Moreover, the current study showed that there is a significant reduction in first and second age categories in ALP level ($P=0.003$, 0.000) respectively.

This is supported by the fact that a significantly lower level of serum Parathyroid hormone after SG, ALP which is the marker of bone resorption is decreased [39].

In this study when compare between the level INR according to the age, we found that there is significant difference ($P=0.006$) between patients before and after 6 months of surgery through the first age category only, and that is similarly with [40] whose said that age have effect on INR level. This is might be due to the metabolic alterations can influence the coagulation cascade and clotting factors, leading to changes in INR [41], because the metabolism slows with age due to loss of muscle tissue, but also due to hormonal and neurological changes.

The prevalence of obesity is dramatically rising at present, making it a public health issue [42]. The liver is one of the largest lymphoid organs in the human body. A primary line of defence, it modulates the inflammatory response in autoimmune diseases [43, 44].

■ CONCLUSION

The excess weight loss tended to increase with decreasing age. AST, ALT, ALP this enzyme levels before and after the surgery can provide insights into liver function and potential liver-related effects of the procedure and age have effect on INR level.

■ REFERENCES

1. Lustig R.H., Collier D., Kassotis C., Roepeke T.A., Kim M.J., Blanc E., Barouki R., Bansal A., Cave M.C., Chatterjee S., Choudhury M., Gilbertson M., Lagadic-Gossman D., Howard S., Lind L., Tomlinson C.R., Vondracek J., Heindel J.J. Obesity I: Overview and molecular and biochemical mechanisms. *Biochem Pharmacol.* 2022;199:115012. doi: 10.1016/j.bcp.2022.115012
2. Deurenberg P, Yap M. The assessment of obesity: methods for measuring body fat and global prevalence of obesity. *Baillieres Best Pract Res Clin Endocrinol Metab.* 1999;13(1):1–11. doi: 10.1053/beem.1999.0003
3. Djalalinia S., Saeedi Moghaddam S., Sheidaei A., Rezaei N., Naghibi Irvani S.S., Modirian M., Zokaei H., Yoosefi M., Gohari K., Kousha A., Abdi Z., Naderimagham S., Soroush A.R., Larijani B., Farzadfar F. Patterns of Obesity and Overweight in the Iranian Population: Findings of STEPs 2016. *Front Endocrinol (Lausanne).* 2020;11:42. doi: 10.3389/fendo.2020.00042
4. Templin T., Cravo Oliveira Hashiguchi T., Thomson B., Dieleman J., Bendavid E. The overweight and obesity transition from the wealthy to the poor in low- and middle-income countries: A survey of household data from 103 countries. *PLoS Med.* 2019;16(11):e1002968. doi: 10.1371/journal.pmed.1002968
5. Valenzuela P.L., Carrera-Bastos P., Castillo-García A., Lieberman D.E., Santos-Lozano A., Lucia A. Obesity and the risk of cardiometabolic diseases. *Nat Rev Cardiol.* 2023;20(7):475–494. doi: 10.1038/s41569-023-00847-5
6. Hakim M., Alwan M., Nakhle M., Khazen G., Al-Hajj G., Chemaly R. Is concomitant cholecystectomy at the time of bariatric surgery justified? A retrospective study. *Surgery Open Digestive Advance.* 2023;9:100082.
7. Kang J.H., Le Q.A. Effectiveness of bariatric surgical procedures: A systematic review and network meta-analysis of randomized controlled trials. *Medicine (Baltimore).* 2017;96(46):e8632. doi: 10.1097/MD.00000000000008632
8. Deng J., Wei W., Chen Z., Lin B., Zhao W., Luo Y., Zhang X. Engineered Liver-on-a-Chip Platform to Mimic Liver Functions and Its Biomedical Applications: A Review. *Micromachines (Basel).* 2019;10(10):676. doi: 10.3390/mi10100676
9. Al Danaf L., Hussein Kamareddine M., Fayad E., Hussain A., Farhat S. Correlation between Fibroscan and laboratory tests in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis patients for assessing liver fibrosis. *World J Hepatol.* 2022;14(4):744–753. doi: 10.4254/wjh.v14.i4.744



10. Kasarala G, Tillmann H.L. Standard liver tests. *Clin Liver Dis (Hoboken)*. 2016;8(1):13–18. doi: 10.1002/cld.562
11. Maan W, Warsi Q.A., Rashed A., Karjoo M. Unexplained high activity of aspartate aminotransferase in an asymptomatic pediatric patient. *International Journal of Pediatrics*. 2017;5(10):5805–5808.
12. Panteghini M.B.R., Van Solinge W.W. *Tietz textbook of clinical chemistry and molecular diagnostics*. 5th ed. Elsevier Health Sciences, 2006.
13. Lord R., Fahie-Wilson M., Suri S. A paediatric case of macro aspartate aminotransferase. *Ann Clin Biochem*. 2008;45(Pt 3):323–4. doi: 10.1258/acb.2007.007094
14. Yulia A., Wijesiriwardana A. Extremely high isolated maternal alkaline phosphatase serum concentration-2 case reports. *Int J Pregn & Chi Birth*. 2017;2(4):111–113.
15. Singh I., Noel G., Barker J.M., Chatfield K.C., Furniss A., Khanna A.D., Nokoff N.J., Patel S., Pyle L., Nahata L., Cole F.S., Ikomi C., Bamba V., Fechner P.Y., Davis S.M. Hepatic abnormalities in youth with Turner syndrome. *Liver Int*. 2022;42(10):2237–2246. doi: 10.1111/liv.15358
16. Mohammed A.K., Mokif T.A., Hadwan M.H. The effect of Morbid Obesity on the Liver Function Enzymes. *Research Journal of Pharmacy and Technology*. 2019;12(5):2241–2244.
17. Altoub S.A., Alenazi A.A., Bukhari T., Abdo S., Alenzi F.Q. PT and PTT: Are They Significant Indicators of Poor Prognosis in Severe Renal Failure Patients? *Acta Biomed*. 2023;94(2):e2023118.
18. Kamal A.H., Tefferi A., Pruthi R.K. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. *Mayo Clin Proc*. 2007;82(7):864–73. doi: 10.4065/82.7.864
19. Donaldson M.D., Gault E.J., Tan K.W., Dunger D.B. Optimising management in Turner syndrome: from infancy to adult transfer. *Arch Dis Child*. 2006;91(6):513–20. doi: 10.1136/adc.2003.035907
20. Meyer R.E., Thompson S.J., Addy C.L., Garrison C.Z., Best R.G. Maternal serum placental alkaline phosphatase level and risk for preterm delivery. *Am J Obstet Gynecol*. 1995;173(1):181–6. doi: 10.1016/0002-9378(95)90187-6
21. Moolenaar L.R., de Waard N.E., Heger M., de Haan L.R., Sloommaekers C.P.J., Nijboer W.N., Tushuizen M.E., van Golen R.F. Liver Injury and Acute Liver Failure After Bariatric Surgery: An Overview of Potential Injury Mechanisms. *J Clin Gastroenterol*. 2022;56(4):311–323. doi: 10.1097/MCG.0000000000001662
22. Grimm I.S., Schindler W., Haluszka O. Steatohepatitis and fatal hepatic failure after biliopancreatic diversion. *Am J Gastroenterol*. 1992;87(6):775–9.
23. Kirkpatrick V., Moon R.C., Teixeira A.F., Jawad M.A. Cirrhosis following single anastomosis duodeno-ileal switch: A case report. *Int J Surg Case Rep*. 2018;45:130–132. doi: 10.1016/j.ijscr.2018.03.021
24. Fakhry T.K., Mhaskar R., Schwitala T., Muradova E., Gonzalo J.P., Murr M.M. Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis. *Surg Obes Relat Dis*. 2019;15(3):502–511. doi: 10.1016/j.soard.2018.12.002
25. Luo R.B., Suzuki T., Hooker J.C., Covarrubias Y., Schlein A., Liu S., Schwimmer J.B., Reeder S.B., Funk L.M., Greenberg J.A., Campos G.M., Sandler B.J., Horgan S., Sirlin C.B., Jacobsen G.R. How bariatric surgery affects liver volume and fat density in NAFLD patients. *Surg Endosc*. 2018;32(4):1675–1682. doi: 10.1007/s00464-017-5846-9
26. Bower G., Toma T., Harling L., Jiao L.R., Efthimiou E., Darzi A., Athanasios T., Ashrafian H. Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: a Systematic Review of Liver Biochemistry and Histology. *Obes Surg*. 2015;25(12):2280–9. doi: 10.1007/s11695-015-1691-x
27. Lassailly G., Caiazzo R., Buob D., Pigeyre M., Verkindt H., Labreuche J., Raverdy V., Leteurtre E., Dharancy S., Louvet A., Romon M., Duhamel A., Pattou F., Mathurin P. Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. *Gastroenterology*. 2015;149:379–388; quiz e15–16.
28. Nguyen N.T., Brethauer S.A., Morton J.M., Ponce J., Rosenthal R.J. (Eds.). *The ASMBS textbook of bariatric surgery Cham: Springer International Publishing*. 2020:3–356.
29. Woźniewska P., Diemiszczczyk I., Groth D., Szczecińska B., Choromańska B., Blachnio-Zabielska A., Krętkowski A., Hady H.R. The influence of patient's age on metabolic and bariatric results of laparoscopic sleeve gastrectomy in 2-year observation. *BMC Surg*. 2020;20(1):323. doi: 10.1186/s12893-020-00989-0
30. Chang W.W., Hawkins D.N., Brockmeyer J.N., Faler B.J., Hoppe S.W., Prasad B.M. Factors influencing long-term weight loss after bariatric surgery. *Surg Obes Relat Dis*. 2019;15(3):456–461. doi: 10.1016/j.soard.2018.12.033
31. Sisik A., Basak F. Presurgical Predictive Factors of Excess Weight Loss After Laparoscopic Sleeve Gastrectomy. *Obes Surg*. 2020;30(8):2905–2912. doi: 10.1007/s11695-020-04624-y
32. Ockell J., Elander A., Staalesen T., Olsén M.F. Evaluation of excess skin in Swedish adults 18–59 years of age. *J Plast Surg Hand Surg*. 2017;51(2):99–104. doi: 10.1080/2000656X.2016.1187157
33. Stanford F.C., Mushannan T., Cortez P., Campoverde Reyes K.J., Lee H., Gee D.W., Pratt J.S., Boepple P.A., Bredella M.A., Misra M., Singhal V. Comparison of Short and Long-Term Outcomes of Metabolic and Bariatric Surgery in Adolescents and Adults. *Front Endocrinol (Lausanne)*. 2020;11:157. doi: 10.3389/fendo.2020.00157
34. Venâncio F.A., Almeida L.A., Zovico P.V., Barauna V.G., Miguel G.P.S., Pedrosa R.G., Haraguchi F.K. Roux-en-Y Gastric Bypass and Sleeve Gastrectomy Differently Affect Oxidative Damage Markers and their Correlations with Body Parameters. *Obes Surg*. 2021;31(4):1680–1687. doi: 10.1007/s11695-020-05179-8
35. Lee Y., Doumouras A.G., Yu J., Brar K., Banfield L., Gmora S., Anvari M., Hong D. Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol*. 2019;17(6):1040–1060.e11. doi: 10.1016/j.cgh.2018.10.017
36. Laursen T.L., Hagemann C.A., Wei C., Kazankov K., Thomsen K.L., Knop F.K., Grønbaek H. Bariatric surgery in patients with non-alcoholic fatty liver disease – from pathophysiology to clinical effects. *World J Hepatol*. 2019;11(2):138–149. doi: 10.4254/wjh.v11.i2.138
37. Goh G.B., Schauer P.R., McCullough A.J. Considerations for bariatric surgery in patients with cirrhosis. *World J Gastroenterol*. 2018;24(28):3112–3119. doi: 10.3748/wjg.v24.i28.3112
38. Billeter A.T., Senft J., Gotthardt D., Knefel P., Nickel F., Schulte T., Fischer L., Nawroth P.P., Büchler M.W., Müller-Stich B.P. Combined Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Sleeve Gastrectomy or Gastric Bypass? a Controlled Matched Pair Study of 34 Patients. *Obes Surg*. 2016;26(8):1867–74. doi: 10.1007/s11695-015-2006-y
39. Jaruvongvanich V., Vantasiri K., Upala S., Ungprasert P. Changes in bone mineral density and bone metabolism after sleeve gastrectomy: a systematic review and meta-analysis. *Surg Obes Relat Dis*. 2019;15(8):1252–1260. doi: 10.1016/j.soard.2019.06.006
40. Sultana A., Hussain F., Asif R., Bhutto A. To Determine the Effect of Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT), and International Normalized Ratio (INR) Levels on Gender and Age. *Pakistan Journal of Medical & Health Sciences*. 2023;17(01):729–729.
41. Grover S.P., Mackman N. Tissue factor: an essential mediator of hemostasis and trigger of thrombosis. *Arterioscler Thromb Vasc Biol*. 2018;38:709–725.
42. Latif F.J.A., Al Sawafi A.G., & Ali D.S. The Relation of Biomarkers in Serum Non-Alcohol Fatty Liver Disease with Diabetes Mellitus Type 2 and NAFLD Obese among Adults in Basrah Governorate. *Biomedicine and Chemical Sciences*. 2023;2(1):16–22.
43. Adlan M.M. & Kata F.S. Estimation of some functional testing of Liver, kidney and some of lipid profiles of women suffering from rheumatoid arthritis. *Journal of Basrah Researches (Sciences)*. 2021;47(1):1–8.
44. Al-Hayder M.N., Al-Mayyahi R.S. & Abdul-Razak A.S. Effects of sun flower oils and beef tallow on serum parameters and liver histopathology in experimental rats. *Obesity Medicine*. 2020;18:100232. <https://doi.org/10.1016/j.jobmed.2020.100232>